UBS analyst Karl Keirstead maintains Salesforce (NYSE:CRM) with a Neutral and lowers the price target from $180 to $162.
Here’s How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Abbott Laboratories (NYSE:ABT) has outperformed the market over the past 10 years by 1.04% on an annualized basis…